Response to therapy in 37 patients with HIV-related thrombocytopenic purpura. NLM AIDSLINE Important note: Information in this article was accurate in 1988. The state of the art may have changed since the publication date.

Click here to return to AIDSLINE main menu
DonateNow
Print this Article


Response to therapy in 37 patients with HIV-related thrombocytopenic purpura.

Br J Haematol. 1987 Aug;66(4):491-5. Unique Identifier : AIDSLINE MED/88024772
Oksenhendler E; Bierling P; Farcet JP; Rabian C; Seligmann M; Clauvel JP; Department of Clinical Immunopathology and Haematology, Hopital; Saint-Louis, Paris, France.

Abstract: Thirty-seven patients belonging to the major AIDS-risk groups and with serum antibodies to the human immunodeficiency virus (HIV), were evaluated and treated between 1983 and 1986 because of profound chronic thrombocytopenia with clinical bleeding. Fifteen out of 26 patients achieved a significant response while on prednisone therapy. Six of them sustained their platelet count above 50 x 10(9)/1 following cessation of steroids. High dose intravenous immunoglobulin therapy gave a satisfactory initial response rate in 12 of 17 patients. Only two of 18 patients responded to danazol. Splenectomy was successful in 10 of 14 patients.
Keywords: Adult AIDS-Related Complex/*THERAPY Danazol/THERAPEUTIC USE Evaluation Studies Female Human Immunization, Passive Male Middle Age Prednisone/THERAPEUTIC USE Purpura, Thrombocytopenic/*THERAPY Splenectomy Time Factors JOURNAL ARTICLE

KWDadultaids-relatedcomplex/KWDtherapydanazol/therapeuticuseevaluationstudiesfemalehumanimmunization,passivemalemiddleageprednisone/therapeuticusepurpura,thrombocytopenic/KWDtherapysplenectomytimefactorsjournalarticle
880228
M8820358

Copyright © 1988 - National Library of Medicine. Reproduced under license with the National Library of Medicine, Bethesda, MD.

AEGiS is a 501(c)3, not-for-profit, tax-exempt, educational corporation. AEGiS is made possible through unrestricted funding from Boehringer Ingelheim, Bridgestone/Firestone Charitable Trust, Bristol-Myers Squibb Company, Elton John AIDS Foundation, Gill Foundation, the National Library of Medicine, Quest Diagnostics, Roche and Trimeris, and donations from users like you. Always watch for outdated information. This article first appeared in 1988. This material is designed to support, not replace, the relationship that exists between you and your doctor.

AEGiS presents published material, reprinted with permission and neither endorses nor opposes any material. All information contained on this website, including information relating to health conditions, products, and treatments, is for informational purposes only. It is often presented in summary or aggregate form. It is not meant to be a substitute for the advice provided by your own physician or other medical professionals. Always discuss treatment options with a doctor who specializes in treating HIV.

Copyright ©1980, 1988. AEGiS. All materials appearing on AEGiS are protected by copyright as a collective work or compilation under U.S. copyright and other laws and are the property of AEGiS, or the party credited as the provider of the content. .